Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q01726

UPID:
MSHR_HUMAN

ALTERNATIVE NAMES:
Melanocortin receptor 1

ALTERNATIVE UPACC:
Q01726; Q66K38; Q6UR93; Q8WWX6; Q8WWX7; Q96I33; Q96RU4; Q9UBF7; Q9UN58; Q9UN59; Q9UN60; Q9UN61; Q9UN62

BACKGROUND:
Melanocortin receptor 1, known for its critical function in melanogenesis, is activated by MSH and ACTH. This activation through G proteins leads to increased adenylate cyclase activity, essential for the production of pigments eumelanin and phaeomelanin in melanocytes. These pigments are key to determining the color of skin, hair, and eyes.

THERAPEUTIC SIGNIFICANCE:
The link between Melanocyte-stimulating hormone receptor and susceptibility to cutaneous malignant melanoma 5 highlights its therapeutic potential. Exploring this receptor's mechanism could lead to groundbreaking treatments for pigmentation anomalies and melanoma, offering hope for targeted skin cancer therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.